JGC
IART icon

J. Goldman & Co’s Integra LifeSciences IART Stock Holding History

J. Goldman & Co’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-570,000
Closed -$12.9M – 543
2024
Q4 		$12.9M Hold
570,000
– – 0.34% 89
2024
Q3 		$10.4M Buy
+570,000
New +$13.2M 0.29% 103

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

J. Goldman & Co's IART Position: Q1 2026 in Review

J. Goldman & Co sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 1,243,772 shares — an estimated $15.4M sold.

J. Goldman & Co first reported a position in IART in Q2 2020 and held it in 6 quarters. The position peaked at $15.4M in Q4 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • J. Goldman & Co reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 1,243,772 Integra LifeSciences shares in Q1 2026, an estimated $15.4M.
  • J. Goldman & Co first reported a position in Integra LifeSciences in Q2 2020 and held it in 6 quarters.
  • J. Goldman & Co's Integra LifeSciences position peaked at $15.4M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.